UA41887C2 - Фармацевтична композиція, що зазнає ерозію - Google Patents

Фармацевтична композиція, що зазнає ерозію

Info

Publication number
UA41887C2
UA41887C2 UA94129170A UA94129170A UA41887C2 UA 41887 C2 UA41887 C2 UA 41887C2 UA 94129170 A UA94129170 A UA 94129170A UA 94129170 A UA94129170 A UA 94129170A UA 41887 C2 UA41887 C2 UA 41887C2
Authority
UA
Ukraine
Prior art keywords
erosion
pharmaceutical composition
matrix
range
active substance
Prior art date
Application number
UA94129170A
Other languages
English (en)
Russian (ru)
Inventor
Мартін Хауард Інфелд
Хауард Инфелд Мартин
А. Вазім МАЛІК
Вазим Малик А.
Навніт Харговіндас ША
Харговиндас Шах Навнит
Вантані ФУАПРАДІТ
Фаупрадит Вантани
Original Assignee
Ф.Хоффманн-Ля Рош Аг
Ф. Хоффманн Ля Рош Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ф.Хоффманн-Ля Рош Аг, Ф. Хоффманн Ля Рош Аг filed Critical Ф.Хоффманн-Ля Рош Аг
Publication of UA41887C2 publication Critical patent/UA41887C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Винахід відноситься до фармацевтичної композиції, що зазнає ерозії. Ця фармацевтична композиція формована і спресована в лікарську форму, яка забезпечує регульоване вивільнення нульового порядку терапевтично активної речовини, диспергированої в полімерній матриці. Композиція містить від 5% до 60% (вага/вага) терапевтично активної речовини, що має розчинність у воді при температурі 25 °С не більш, ніж 80 мг/мл, а також не менш ніж 5% та до 50% (вага/вага) низьков'язкої гідроксипропілметилцелюлози, яка містить 19-30% метоксигруп, 7-12% оксипропільних груп, має ступінь метоксизаміщення від 1,1 до 2,0 і молекулярну масу від 20000 до 26000 Д. 2%-ний (вага/вага) розчин полімеру має в'язкість при температурі 25 °С в межах від 50 до 100 сП, а решту частини композиції складають інертні носії. Матриця виконана без зовнішнього полімерного покриття і розчиняється шляхом ерозії після гідратації зовнішнього гідратованого шару матриці, а швидкість вивільнення активної речовини в одиницю часу залишається по суті незмінною протягом всього часу дії композиції.
UA94129170A 1993-12-13 1994-12-12 Фармацевтична композиція, що зазнає ерозію UA41887C2 (uk)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/166,123 US5393765A (en) 1993-12-13 1993-12-13 Pharmaceutical compositions with constant erosion volume for zero order controlled release

Publications (1)

Publication Number Publication Date
UA41887C2 true UA41887C2 (uk) 2001-10-15

Family

ID=22601916

Family Applications (1)

Application Number Title Priority Date Filing Date
UA94129170A UA41887C2 (uk) 1993-12-13 1994-12-12 Фармацевтична композиція, що зазнає ерозію

Country Status (22)

Country Link
US (1) US5393765A (uk)
EP (1) EP0662322B1 (uk)
JP (1) JP2966745B2 (uk)
KR (1) KR950016783A (uk)
CN (1) CN1110135A (uk)
AT (1) ATE214919T1 (uk)
AU (1) AU688807B2 (uk)
BR (1) BR9404953A (uk)
CA (1) CA2136118A1 (uk)
CO (1) CO4340618A1 (uk)
CZ (1) CZ287718B6 (uk)
DE (1) DE69430237T2 (uk)
ES (1) ES2171431T3 (uk)
HU (1) HU219227B (uk)
IL (1) IL111920A (uk)
NO (1) NO944803L (uk)
NZ (1) NZ270058A (uk)
PL (1) PL306245A1 (uk)
RU (1) RU2174832C2 (uk)
TW (1) TW438597B (uk)
UA (1) UA41887C2 (uk)
ZA (1) ZA949711B (uk)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5945125A (en) * 1995-02-28 1999-08-31 Temple University Controlled release tablet
US5869079A (en) † 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US5783212A (en) * 1996-02-02 1998-07-21 Temple University--of the Commonwealth System of Higher Education Controlled release drug delivery system
US5948437A (en) * 1996-05-23 1999-09-07 Zeneca Limited Pharmaceutical compositions using thiazepine
GB9611328D0 (en) * 1996-05-31 1996-08-07 Zeneca Ltd Pharmaceutical compositions
US6551616B1 (en) * 1997-04-11 2003-04-22 Abbott Laboratories Extended release formulations of erythromycin derivatives
US6010718A (en) * 1997-04-11 2000-01-04 Abbott Laboratories Extended release formulations of erythromycin derivatives
US20050064033A1 (en) * 1997-04-11 2005-03-24 Notario Gerard F. Extended release formulations of erythromycin derivatives
US6337091B1 (en) 1997-10-27 2002-01-08 Temple University - Of The Commonwealth System Of Higher Education Matrix for controlled delivery of highly soluble pharmaceutical agents
US6197340B1 (en) * 1998-05-28 2001-03-06 Medical Research Institute Controlled release lipoic acid
US6214381B1 (en) 1998-09-08 2001-04-10 Effcon, Inc. Methazolamide composition and method of use
US20020169145A1 (en) * 1998-10-14 2002-11-14 Rajen Shah Sustained release pharmaceutical composition and method of releasing pharmaceutically active agent
US6555139B2 (en) 1999-06-28 2003-04-29 Wockhardt Europe Limited Preparation of micron-size pharmaceutical particles by microfluidization
US6503528B1 (en) 1999-11-19 2003-01-07 Abbott Laboratories Polymeric compositions and a method of making the same
US6936275B2 (en) 1999-12-20 2005-08-30 Scolr, Inc. Amino acid modulated extended release dosage form
WO2003024427A1 (en) 1999-12-20 2003-03-27 Temple University Of The Commonwealth System Of Higher Education Tableted oral extended release dosage form
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US6565882B2 (en) * 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
US6242003B1 (en) 2000-04-13 2001-06-05 Novartis Ag Organic compounds
US20020068078A1 (en) * 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
US6541014B2 (en) * 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
US20020197314A1 (en) * 2001-02-23 2002-12-26 Rudnic Edward M. Anti-fungal composition
US20060127474A1 (en) * 2001-04-11 2006-06-15 Oskar Kalb Pharmaceutical compositions comprising fluvastatin
CA2409552A1 (en) 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US20030104052A1 (en) * 2001-10-25 2003-06-05 Bret Berner Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US20030152622A1 (en) * 2001-10-25 2003-08-14 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral diuretic
US20030091630A1 (en) * 2001-10-25 2003-05-15 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
JP2005526079A (ja) * 2002-03-15 2005-09-02 サイプレス バイオサイエンス， インコーポレイテッド 内蔵痛症候群を処置するためのｎｅおよび５−ｈｔ再取り込み阻害剤
US20040043073A1 (en) * 2002-06-14 2004-03-04 Chih-Ming Chen Pharmaceutical compositions for drugs having pH-dependent solubility
US20060003004A1 (en) * 2002-10-25 2006-01-05 Collegium Pharmaceutical, Inc. Pulsatile release compositions of milnacipran
US20040121010A1 (en) * 2002-10-25 2004-06-24 Collegium Pharmaceutical, Inc. Pulsatile release compositions of milnacipran
AU2004207578B2 (en) * 2003-01-28 2007-06-28 Collegium Pharmaceutical, Inc. Multiparticulate compositions of milnacipran for oral administration
US20040185097A1 (en) * 2003-01-31 2004-09-23 Glenmark Pharmaceuticals Ltd. Controlled release modifying complex and pharmaceutical compositions thereof
US7063862B2 (en) * 2003-06-03 2006-06-20 Biokey, Inc. Pharmaceutical composition and method for treating
PL1638529T3 (pl) * 2003-06-16 2017-03-31 Andrx Pharmaceuticals, Llc. Kompozycja doustna o przedłużonym uwalnianiu
AU2004258944B2 (en) 2003-07-21 2011-02-10 Shionogi, Inc. Antibiotic product, use and formulation thereof
CA2533178C (en) * 2003-07-21 2014-03-11 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
CA2533292C (en) * 2003-07-21 2013-12-31 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
EP1653925A1 (en) * 2003-08-11 2006-05-10 Advancis Pharmaceutical Corporation Robust pellet
JP2007502294A (ja) 2003-08-12 2007-02-08 アドバンシス ファーマスーティカル コーポレイション 抗生物質製剤、その使用法及び作成方法
WO2005023184A2 (en) * 2003-08-29 2005-03-17 Advancis Pharmaceuticals Corporation Antibiotic product, use and formulation thereof
CA2538064C (en) * 2003-09-15 2013-12-17 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
AU2004308419B2 (en) * 2003-12-24 2011-06-02 Victory Pharma, Inc. Enhanced absorption of modified release dosage forms
EP1771158A4 (en) * 2004-07-02 2008-03-12 Advancis Pharmaceutical Corp TABLET FOR PULSED DELIVERY
US20060024368A1 (en) * 2004-07-30 2006-02-02 Reza Fassihi Compressed composite delivery system for release-rate modulation of bioactives
WO2006031024A1 (en) * 2004-09-15 2006-03-23 Gl Pharmtech Corp. A sustained-release tablet containing doxazosin mesylate
KR100920856B1 (ko) * 2004-11-30 2009-10-09 (주)아모레퍼시픽 선택적 세로토닌 재흡수 억제제의 연장방출 제제 및 그제조방법
US8778924B2 (en) * 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
US8299052B2 (en) 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
WO2009052391A1 (en) * 2007-10-19 2009-04-23 Purdue Research Foundation Solid formulations of crystalline compounds
BRPI1006902A2 (pt) 2009-01-23 2016-02-16 Aziende Chimiche Riunte Angelini Francesco A C R A F S P A formulação farmacêutica ou alimentícia de liberação controlada, processo para a produção de uma forma farmacêutica ou alimentícia, sistema de liberação controlada, e, uso de um sistema de liberação controlada
US9980946B1 (en) 2017-01-25 2018-05-29 Effcon Laboratories, Inc. Extended release methazolamide formulation

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3870790A (en) * 1970-01-22 1975-03-11 Forest Laboratories Solid pharmaceutical formulations containing hydroxypropyl methyl cellulose
US4226849A (en) * 1979-06-14 1980-10-07 Forest Laboratories Inc. Sustained release therapeutic compositions
US4259314A (en) * 1979-12-10 1981-03-31 Hans Lowey Method and composition for the preparation of controlled long-acting pharmaceuticals
US4389393A (en) * 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US4556678A (en) * 1982-06-24 1985-12-03 Key Pharmaceuticals, Inc. Sustained release propranolol tablet
IL70071A (en) * 1982-11-01 1987-12-31 Merrell Dow Pharma Multilayered sustained release pharmaceutical tablets having non-uniform distribution of active ingredient
FR2535202B1 (fr) * 1982-11-03 1985-08-09 Fabre Sa Pierre Comprimes de theophylline a liberation controlee et leur procede de fabrication
US4540566A (en) * 1984-04-02 1985-09-10 Forest Laboratories, Inc. Prolonged release drug dosage forms based on modified low viscosity grade hydroxypropylmethylcellulose
FR2591105B1 (fr) * 1985-12-11 1989-03-24 Moet Hennessy Rech Composition pharmaceutique, notamment dermatologique, ou cosmetique, a base de phases lamellaires lipidiques hydratees ou de liposomes contenant un retinoide ou un analogue structural dudit retinoide tel qu'un carotenoide.
US4786503A (en) * 1987-04-06 1988-11-22 Alza Corporation Dosage form comprising parallel lamine
US5126145A (en) * 1989-04-13 1992-06-30 Upsher Smith Laboratories Inc Controlled release tablet containing water soluble medicament
DK469989D0 (da) * 1989-09-22 1989-09-22 Bukh Meditec Farmaceutisk praeparat
US5284662A (en) * 1990-10-01 1994-02-08 Ciba-Geigy Corp. Oral osmotic system for slightly soluble active agents
SE9003904D0 (sv) * 1990-12-07 1990-12-07 Astra Ab Method for the manufacture of a pharmaceutical dosage form
WO1993006821A1 (en) * 1991-10-04 1993-04-15 Yoshitomi Pharmaceutical Industries, Ltd. Sustained-release tablet
ES2084478T3 (es) * 1992-02-17 1996-05-01 Siegfried Ag Pharma Formas de dosificacion que tienen liberacion prolongada del ingrediente activo.

Also Published As

Publication number Publication date
PL306245A1 (en) 1995-06-26
US5393765A (en) 1995-02-28
CZ312794A3 (en) 1995-09-13
ES2171431T3 (es) 2002-09-16
ZA949711B (en) 1995-08-21
HUT75456A (en) 1997-05-28
EP0662322A2 (en) 1995-07-12
DE69430237D1 (de) 2002-05-02
CO4340618A1 (es) 1996-07-30
CA2136118A1 (en) 1995-06-14
JPH07196535A (ja) 1995-08-01
KR950016783A (ko) 1995-07-20
ATE214919T1 (de) 2002-04-15
RU94043809A (ru) 1996-11-10
IL111920A (en) 1999-08-17
EP0662322B1 (en) 2002-03-27
BR9404953A (pt) 1995-08-08
JP2966745B2 (ja) 1999-10-25
AU688807B2 (en) 1998-03-19
CZ287718B6 (en) 2001-01-17
NZ270058A (en) 1996-07-26
NO944803D0 (no) 1994-12-12
IL111920A0 (en) 1995-03-15
RU2174832C2 (ru) 2001-10-20
HU9403496D0 (en) 1995-02-28
HU219227B (en) 2001-03-28
NO944803L (no) 1995-06-14
DE69430237T2 (de) 2002-07-18
EP0662322A3 (en) 1997-01-29
TW438597B (en) 2001-06-07
CN1110135A (zh) 1995-10-18
AU8023294A (en) 1995-06-22

Similar Documents

Publication Publication Date Title
UA41887C2 (uk) Фармацевтична композиція, що зазнає ерозію
US4842866A (en) Slow release solid preparation
KR950007841A (ko) 트라마돌 염을 함유하는 서방성 약물 제제
IE970588A1 (en) Controlled release pharmaceutical compositions containing tiagabine
NZ325844A (en) A bioadhesive tablet comprising a c16-c22alkyl fumarate as lubricant
US6893660B2 (en) Stable pharmaceutical compositions without a stabilizer
CA2041774A1 (en) Use of cross-linked amylose as a matrix for the slow release of biologically active compounds
CA2290624A1 (en) Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs
NZ332576A (en) Controlled-release pharmaceutical tablet containing a carrier based on cross-linked amylose and hydroxypropylmethylcellulose
KR890004686A (ko) 서방성 에토돌락
CA2045472A1 (en) Drug delivery compositions
CA2354057A1 (en) Sustained release tablet containing hydrocolloid and cellulose ether
CA2264238A1 (fr) Forme galenique a liberation prolongee de milnacipran
US4992277A (en) Immediate release diltiazem formulation
DE69816951D1 (de) Zubereitung enthaltend Cefaclor oder Cephalexin mit modifizierter Freisetzungsmatrix
FR2698788B1 (fr) Composition pharmaceutique effervescente contenant de l'ibuprofène et son procédé de préparation.
CA2157323A1 (en) Gepirone dosage form
KR850700212A (ko) 서방성 약제학적 캼셀제
US4143129A (en) Cephalexin tablets
ID22763A (id) Komposisi penstabil tibolon
KR880004801A (ko) 서방성 약학적 조성물
KR890001559A (ko) 트라피딜을 함유하는 제약 조성물, 그의 제조방법 및 관련된 치료 용도
ATE175870T1 (de) Pharmazeutische zubereitung zur rektalen verabreichung von pharmakologisch wirksamen verbindungen
HUP9902681A2 (hu) Térhálósított amilózt és hidroxi-propil-metil-cellulózt tartalmazó hordozóval készült szabályozott felszabadulású tabletta gyógyszerkészítmény
MY102368A (en) Solid sustained-release composition